Colorectal Cancer

614

Review clinical trials related to Colorectal Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal Cancer

This clinical trial studies how well mind-body interventions work in improving quality of life (QOL), stress, and sleep quality among survivors of breast, prostate, endometrial, or colorectal cancer. For many cancer survivors, the experience of cancer extends well beyond the completion of therapy. Common long-term effects include fatigue, cognitive impairment, anxiety, depression, sleep disturbance, and diminished physical function, all of which contribute to reduced QOL and overall health. Yoga, a mind-body intervention, utilizes breathwork, meditation, and gentle movement to help reduce activity in the body's nervous system. Breathwork and meditation have been shown to improve heart rate variability (a measure of the body's ability to adapt to stress). Movement-based practices may offer added benefit by supporting coordination and physical resiliency, aspects that are often reduced after cancer treatment and can lead to decreased QOL. This trial may help researchers determine whether a mind-body intervention that includes breathwork and meditation, as well as an intervention that includes breathwork and meditation plus gentle movement can work to improve QOL, stress, and sleep quality among survivors of breast, prostate, endometrial, or colorectal cancer.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Roswell Park Cancer InstituteUpdated: Nov 5, 2026
Eligibility criteria

Received a diagnosis of invasive, non-metastatic breast, colorectal, endometrial... [+2]

Individuals with skeletal instabilities, cardio-pulmonary comorbidities, or othe... [+4]

Status: Recruiting

Tislelizumab in People With Colorectal Cancer

The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Nov 6, 2026Locations: 3
Eligibility criteria

Age 18 years or older on date of signing informed consent [+37]

Presence of other active malignancy [+23]

Status: Recruiting

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Nov 5, 2026Locations: 1
Eligibility criteria

"Mutation-Positive Lynch syndrome": carriers or obligate carriers (by pedigree)... [+12]

Individuals with presence of two somatic mutations/loss of heterozygosity (LOH)... [+21]

Status: Recruiting

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve the results of CRS with HIPEC treatment on these tumors by choosing the chemotherapy drugs used in HIPEC. Objective: To see if HIPEC after CRS can be improved, using either a model called the SMART (Sustained Microenvironment for Analysis of Resected Tissue) System or using 3-D cell culture (organoid) models, in order to test different chemotherapy drugs on tumors that were surgically removed prior to HIPEC treatment (these models are not attached to the body) versus tumors that were treated with HIPEC while still inside the body before being immediately surgically removed. Eligibility: Adults ages 18 and older who have peritoneal carcinomatosis that cannot be fully removed safely with surgery. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Electrocardiogram (EKG) Computed tomography (CT) scan Other imaging scans, as needed Tumor biopsy, if needed Laparoscopy (small cuts are made in the abdomen, and a tube with a light and a camera is used to see the organs in the abdomen), if needed Participants will enroll in NIH protocol #13C0176. This allows their tumor samples to be used in future research. Some screening tests may be repeated in the study. Participants will have CRS. As many of their visible tumors will be removed as possible during surgery except for a few specific tumors left to receive the HIPEC treatment. Then they will receive HIPEC and the remaining tumors will be immediately removed. Participants will be in the hospital for 7-21 days after this surgery (CRS with HIPEC). Participants will give tumor, fluid samples (from the abdomen during surgery), blood, saliva, cheek swab, and stool for research. They will complete surveys about their health and quality of life. Participants with peritoneal mesothelioma (mesothelioma primary only) will have genetic (DNA) testing to determine clinical (CLIA level) germline BAP1 status for research use. Participants will have follow-up visits for up to 5 years from CRS with HIPEC. If there is disease progression, participants may have CRS with HIPEC again. Participants will then have follow-up visits for up to 5 years from the date of last CRS with HIPEC. ...

Participants needed: 60
Trial details
Phase: Phase 1Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Confirmation of peritoneal carcinomatosis from peritoneal mesothelioma or atypic... [+13]

Participants with known extra-abdominal metastatic disease from the participant... [+7]

Status: Recruiting

Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol. Design Patients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.

Participants needed: 7,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Not listed

Status: Not yet recruiting

Alberta Cancer Exercise Dose in Colorectal Cancer

The purpose of this pilot randomized, wait-list controlled study is to evaluate the effects of exercise dose in terms of frequency (1 vs. 2 days per week) in individuals on systemic treatment for colorectal cancer. The impact on the individual (physical function, quality of life, fatigue and other patient reported outcomes) as well as on health care utilization (cost to deliver, cost to individuals, savings and impact to the health care system) will be evaluated. In addition, assessments of immunological markers to better understand the biological impact of exercise dose on immunological markers will be explored.

Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of CalgaryUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

Adults (≥18) [+5]

Participants who have completed adjuvant treatment for CRC [+6]

Status: Recruiting

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.

Participants needed: 260
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: PfizerUpdated: Nov 5, 2026Locations: 17
Eligibility criteria

18 years of age or older [+3]

Active malignancy within 3 years prior to enrollment [+10]

Status: Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken alone or together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab with or without capecitabine, with zanidatamab with or without docetaxel, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken alone or together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

Participants needed: 910
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Boehringer IngelheimUpdated: Nov 5, 2026Locations: 104
Eligibility criteria

Patients ≥18 years of age or over the legal age of consent in countries where th... [+7]

Mean resting corrected QT interval (QT interval corrected for heart rate by Frid... [+3]

Status: Not yet recruiting

SAMe in Prevention of Oxaliplatin-associated Liver Injury

This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cedars-Sinai Medical CenterUpdated: Nov 6, 2026Locations: 2
Eligibility criteria

Stage IV patients with resectable liver predominant metastatic colorectal cancer... [+12]

Currently participating in or has participated in a study of an investigational... [+22]

Status: Not yet recruiting

Nurse-Led Prehabilitation Before Major Abdominal Cancer Surgery

Many people who have major planned surgery for abdominal cancer develop complications afterwards, which can prolong hospital stay and slow recovery. This study tests whether a four-week program led by a trained oncology nurse, started before surgery, reduces these complications. The program combines supervised and home exercise (walking, resistance and breathing exercises), nutrition counseling with protein targets and supplements when needed, education and relaxation techniques to reduce anxiety, and advice on stopping smoking and alcohol. Adults at one hospital will be randomly assigned, in equal numbers, to the program plus usual care or to usual care alone; 104 participants are planned. The main outcome is the Comprehensive Complication Index, a score from 0 to 100 that combines all complications within 30 days after surgery, graded by an assessor who does not know the group. Other outcomes include serious complications, distance walked in six minutes, quality of life, length of hospital stay, hospital readmission, time to first getting out of bed, and adherence to the program. In a qualitative part, 12 to 15 participants from the program group will be interviewed about their experiences, barriers and acceptability. Results from both parts will be combined to interpret the findings.

Participants needed: 104
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Alexandria UniversityUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

Adults aged 18 years or older [+4]

Emergency or urgent surgery [+4]

Status: Recruiting

Outcomes of Knife-Assisted Full-Thickness Resection for Rectal Lesions: A Multicenter Study

This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Current methods for removing early rectal tumors each have limits depending on the size and location of the growth. This study collects data from hospitals in multiple countries to find out how well kFTR works and how safe it is. Researchers review medical records and endoscopy reports from patients who already had kFTR at participating hospitals. The main measures are whether the procedure was completed successfully, whether the growth was removed in one piece, whether the edges were cancer-free, and how often complications occurred. The study also tracks hospital stay length, need for additional surgery, cancer recurrence, and death.

Participants needed: 150
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University Hospital, GhentUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

Patients aged 18 years and older [+1]

Unavailable information regarding kFTR technical outcomes

Status: Not yet recruiting

Tailored Nutrition vs. Exercise Prehabilitation Before Colorectal Cancer Surgery

This study will test whether tailored nutritional support before surgery, alone or combined with a structured exercise program, can help adult patients recover better after surgery for colorectal (bowel) cancer. Participants will be randomly assigned to one of three groups: usual care, tailored nutritional support alone, or nutritional support combined with a structured exercise program (multimodal prehabilitation). The main goal is to find out whether either approach improves physical function 30 days after surgery, measured by how far participants can walk in 6 minutes (the 6-minute walk test). The study will also look at nutritional intake, physical function, quality of life, complications, hospital readmissions, and length of hospital stay. A total of 140 adult patients scheduled for surgery for colorectal cancer at hospitals in Northern Norway will be enrolled.

Participants needed: 140
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital of North NorwayUpdated: Nov 6, 2026Locations: 2
Eligibility criteria

Planned elective surgery for colorectal cancer [+4]

Known metastatic disease [+10]

Status: Not yet recruiting

Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach

This is a mixed-methods implementation pilot combining an educational intervention with a mailed stool-based testing outreach feasibility study within a resident primary care clinic. Participants will be assigned by clinic team to education, mailed FIT, mailed Cologuard, or usual care comparison groups.

Participants needed: 200
Trial details
Age: 45-75Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Nov 5, 2026Locations: 1
Eligibility criteria

Previously enrolled in prior study IRB #202202059 who agreed to participate in f...

Not enrolled in prior study IRB #202202059 [+6]

Status: Recruiting

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care (SOC) cetuximab or bevacizumab + chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: GenmabUpdated: Nov 3, 2026Locations: 5
Eligibility criteria

Histologically or cytologically confirmed colorectal adenocarcinoma that is recu... [+3]

BRAF V600 mutation (eg, V600E) and/or microsatellite instability-high/deficient... [+5]

Status: Not yet recruiting

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).

Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Nov 5, 2026Locations: 1
Eligibility criteria

Histologically or cytologically confirmed CRC. [+16]

Patients with MSI-H status. [+27]

Status: Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Nov 4, 2026Locations: 42
Eligibility criteria

Is at least 18 years of age inclusive at the time of signing the informed consen... [+12]

Has known or suspected leptomeningeal disease and/or untreated brain metastasis. [+17]

Status: Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.

Participants needed: 7,000
Trial details
Age: 40+Biological sex: AllType: ObservationalSponsor: Adela, IncUpdated: Nov 4, 2026Locations: 17
Eligibility criteria

Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagno... [+2]

Currently receiving any treatment for cancer [+12]

Status: Recruiting

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Participants needed: 300
Trial details
Age: 60+Biological sex: AllType: ObservationalSponsor: Wake Forest University Health SciencesUpdated: Nov 5, 2026Locations: 147
Eligibility criteria

Newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC... [+5]

Patients enrolled on hospice. [+4]

Status: Recruiting

A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion

Colorectal cancer (CRC) has shifted toward a patient-personalized precision medicine paradigm; however, the high heterogeneity and complex tumor microenvironment (TME) of CRC restrict the development of individualized therapy, and existing preclinical models and multi-omics technologies are insufficient to broadly benefit patients. Building on previous research, this project intends to use 3D multicellular bioprinting (3DMP) to incorporate key TME components-cancer-associated fibroblasts (CAFs) and PBMC immune cells-to construct patient-derived CRC-CAFs/PBMC 3DMP models, aiming to apply them to personalized clinical drug screening and prognosis prediction, and to combine them with multi-omics technologies to advance preclinical research on CRC. The implementation of this study will help address the bottleneck of the lack of broadly applicable preclinical models for advancing CRC precision therapy. It has major clinical translational value, will bring significant changes to CRC preclinical research platforms, and will help promote the development of cancer precision medicine.

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Peking Union Medical College HospitalUpdated: Nov 5, 2026Locations: 1Duration: 60 Months
Eligibility criteria

More than 18 years old [+2]

Medical history with other malignancies or serious diseases [+1]

Status: Not yet recruiting

GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer

This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).

Participants needed: 368
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Genfleet Therapeutics (Shanghai) Inc.Updated: Nov 3, 2026
Eligibility criteria

Willing to participate in the study and provide written informed consent [+9]

Other malignancy that has progressed or required treatment within 3 years prior... [+14]

Status: Recruiting

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Participants needed: 152
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: LTZ Therapeutics, Inc.Updated: Nov 3, 2026Locations: 1
Eligibility criteria

Advanced /metastatic colorectal tumors that have failed standard treatments [+3]

Active infection with hepatitis B or C [+6]

Status: Recruiting

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Participants needed: 200
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Immunome, Inc.Updated: Nov 3, 2026Locations: 5
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 [+23]

Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1... [+6]

Status: Recruiting

Researching the Effect of Exercise on Cancer

Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.

Participants needed: 51
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: City of Hope Medical CenterUpdated: Nov 3, 2026Locations: 9
Eligibility criteria

Stage 3 or [+12]

Enrollment onto any other interventional investigational study except interventi... [+3]

Status: Recruiting

Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery

Evaluate the safety and efficacy of postoperative Pre-emptive EVT (PEVT) in reducing the incidence of anastomotic leaks within 30 days after surgery in patients with colorectal cancer. Compare the differences between the PEVT group and the control group in terms of operation time, length of hospital stay, and total medical costs. Analyze the incidence of other postoperative complications in the two groups, such as wound infection, abdominal abscess, and intestinal obstruction. Assess the impact of PEVT on postoperative recovery indicators, including time to first flatus, time to first defecation, and time to ambulation. Observe the occurrence of PEVT-related adverse events, such as device displacement, bleeding, and infection.

Participants needed: 110
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Nanchong Central HospitalUpdated: Nov 2, 2026Locations: 1
Eligibility criteria

Pathologically diagnosed with colorectal cancer, planned for radical surgery (ri... [+3]

Preexisting anastomotic leakage or severe intra-abdominal infection before surge... [+6]

Status: Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Participants needed: 560
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GenmabUpdated: Nov 2, 2026Locations: 54
Eligibility criteria

Histologically or cytologically confirmed solid tumors with evidence of metastat... [+15]

Central nervous system metastases that are untreated or symptomatic, or require... [+12]